XML 88 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2020
Revenue From Contract With Customer [Abstract]  
Schedule of Disaggregated Revenue

The Company's significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for each of the three months ended March 31, 2020 and 2019 are set forth below (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

 

2020

 

 

2019

 

Generics

 

 

 

 

 

 

 

 

 

 

Anti-Infective

 

$

13,253

 

 

$

5,942

 

 

Hormonal/Allergy

 

 

87,481

 

 

 

102,725

 

 

Antiviral

 

 

15,824

 

 

 

14,456

 

 

Central Nervous System (1)

 

 

101,575

 

 

 

124,775

 

 

Cardiovascular System

 

 

29,679

 

 

 

36,217

 

 

Gastroenterology

 

 

23,536

 

 

 

9,556

 

 

Oncology

 

 

15,966

 

 

 

14,959

 

 

Metabolic Disease/Endocrine

 

 

17,229

 

 

 

17,847

 

 

Respiratory

 

 

10,067

 

 

 

9,218

 

 

Dermatology

 

 

15,245

 

 

 

12,973

 

 

Other therapeutic classes

 

 

21,746

 

 

 

18,177

 

 

International and other

 

 

985

 

 

 

15,632

 

 

   Total Generics net revenue

 

 

352,586

 

 

 

382,477

 

Specialty

 

 

 

 

 

 

 

 

 

 

Hormonal/Allergy

 

 

13,954

 

 

 

10,899

 

 

Central Nervous System (1)

 

 

68,311

 

 

 

42,899

 

 

Gastroenterology

 

 

48

 

 

 

481

 

 

Metabolic Disease/Endocrine

 

 

273

 

 

 

541

 

 

Other therapeutic classes

 

 

5,391

 

 

 

8,823

 

 

   Total Specialty net revenue

 

 

87,977

 

 

 

63,643

 

AvKARE

 

 

 

 

 

 

 

 

 

 

Distribution

 

 

31,586

 

 

 

 

 

Government Label

 

 

21,378

 

 

 

 

 

Institutional

 

 

3,413

 

 

 

 

 

Other

 

 

1,593

 

 

 

 

 

   Total AvKARE net revenue

 

 

57,970

 

 

 

 

 

       Total net revenue

 

$

498,533

 

 

$

446,120

 

 

 

(1)

During the three months ended September 30, 2019, operating results for Oxymorphone were reclassified from Generics to Specialty, where it is sold as a non-promoted product.  Prior period results have not been restated to reflect the reclassification.

 

Schedule of Major Categories of Sales-Related Deductions

A rollforward of the major categories of sales-related deductions for the three months ended March 31, 2020 is as follows (in thousands):

 

 

 

Contract

Charge - Backs

and Sales

Volume

Allowances

 

 

Cash Discount

Allowances

 

 

Accrued

Returns

Allowance

 

 

Accrued

Medicaid and

Commercial

Rebates

 

Balance at December 31, 2019

 

$

829,807

 

 

$

34,308

 

 

$

150,361

 

 

$

114,960

 

Impact from the Acquisitions

 

 

15,292

 

 

 

944

 

 

 

15,229

 

 

 

10

 

Provision related to sales recorded in the period

 

 

1,080,290

 

 

 

32,947

 

 

 

47,163

 

 

 

36,472

 

Credits/payments issued during the period

 

 

(1,244,302

)

 

 

(35,371

)

 

 

(26,301

)

 

 

(40,067

)

Balance at March 31, 2020

 

$

681,087

 

 

$

32,828

 

 

$

186,452

 

 

$

111,375